Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database

Abstract B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy has changed the therapeutic landscape of relapsed/refractory multiple myeloma (RRMM). Despite the efficacy, these products have been associated with an adverse effect profile including cytokine releas...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Raj Shah, Nikhil Vojjala, Tiewei Cheng, Charmi Bhanushali, Sanjana Mullangi, Leyla Shune, Reza Shahzad
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Springer 2026-03-01
Serie:	Annals of Hematology
Soggetti:	Multiple Myeloma CAR-T Relapsed Refractory
Accesso online:	https://doi.org/10.1007/s00277-026-06927-z
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!